Literature DB >> 31247673

Ascitic fluid total protein, a useful marker in non-portal hypertensive ascites.

Shenghua Zhu1, Li Du1, Dong Xu2, Zhiwen Lu1, Ting Xu1, Jin Li3, Keshu Xu1, Jin Ye1, Yuhu Song1.   

Abstract

BACKGROUND AND AIMS: Diagnostic performance of ascitic fluid total protein (AFTP) concentration remained unsettled. Our aim was to determine diagnostic value of AFTP in differential diagnosis of causes of ascites.
METHODS: Seven hundred four consecutive patients with new-onset ascites were prospectively enrolled in this study.
RESULTS: In the training cohort, diagnostic performance of quantitative AFTP assay was superior to that of Rivalta test in differential diagnosis of ascites. At the predetermined cut-off value of 25 g/L, quantitative AFTP assay was more useful in the differentiation of non-portal hypertensive ascites from portal hypertensive ascites compared with the exudate-transudate classification, area under curve of receiver operating characteristic curve was 0.958. Quantitative AFTP assay was superior to serum-ascites albumin gradient in the detection of non-portal hypertensive ascites, especially malignant ascites and tuberculous peritonitis. In mixed ascites, AFTP was useful in identifying peritoneal lesions.
CONCLUSIONS: Ascitic fluid total protein is a useful marker in non-portal hypertensive ascites; thus, it should be determined in diagnostic work-up of the patients with ascites.
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Rivalta test; ascitic fluid total protein; mixed ascites; non-portal hypertension

Year:  2019        PMID: 31247673     DOI: 10.1111/jgh.14768

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  3 in total

1.  Utility of ascitic tumor markers and adenosine deaminase for differential diagnosis of tuberculous peritonitis and peritoneal carcinomatosis.

Authors:  Li Du; Xiuqi Wei; Zhuanglong Xiao; Hui Wang; Yuhu Song
Journal:  BMC Gastroenterol       Date:  2022-09-17       Impact factor: 2.847

2.  Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor.

Authors:  Jian Wang; Zhe-Xiang Feng; Tao Ren; Wei-Yu Meng; Imran Khan; Xing-Xing Fan; Hu-Dan Pan; Liang Liu; Yi-Jun Tang; Xiao-Jun Yao; Run-Ze Li; Mei-Fang Wang; Elaine Lai-Han Leung
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

3.  MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis.

Authors:  Li Du; Dongyuan Wang; Xiuqi Wei; Chang Liu; Zhuanglong Xiao; Wei Qian; Yuhu Song; Xiaohua Hou
Journal:  BMC Gastroenterol       Date:  2022-01-21       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.